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OGTT between individuals with normal glucose tolerance (NGT) and individuals with pre-
diabetes and early-stage diabetes (PDED) and whether these differences correlated with blood
glucose kinetics.
RESEARCH DESIGN AND METHODS — Blood and breath samples were collected at
baseline and every 30 min for a 10-h period after ingestion of 75 g glucose isotopically labeled
with 150 mg [U-
13C6]D-glucose.
RESULTS — Age (56  5 vs. 47  3 years) and BMI (31  2 vs. 31  2 kg/m
2) were not
differentbetweenindividualswithNGT(n10)andPDED(n7),respectively.Bloodglucose
concentrations were signiﬁcantly higher in those with PDED compared with those with NGT
from baseline to 4.5 h after glucose ingestion (P  0.05). Glucose-derived breath
13CO2 was
signiﬁcantly lower in individuals with PDED compared with those with NGT from 1 to 3.5 h
after glucose (P  0.05). Peak breath
13CO2 abundance occurred at 4.5 and 3.5 h in individuals
with PDED and NGT, respectively (36.87  3.15 vs. 41.36  1.56‰ delta over baseline).
CONCLUSIONS — These results suggest that this novel breath test method may assist in
recognition of pre-diabetes or early-stage diabetes in at-risk persons without the need for inva-
sive blood sampling, thus making it an attractive option for large-scale testing of at-risk popu-
lations, such as children.
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T
ype 2 diabetes and its cluster of dis-
orders (i.e., metabolic syndrome)
have become a major public health
concern (1,2) and form a predictive risk
proﬁle for cardiovascular disease (3–5).
Recently, the risk of development of met-
abolic syndrome has signiﬁcantly in-
creased in the pediatric population (6).
Traditionally, pre-diabetes and early-
stage diabetes are assessed in at-risk adult
and pediatric populations using a stan-
dard oral glucose tolerance test (OGTT)
requiring repeated invasive blood sam-
plingoverthe2to3hafteraglucoseload.
Postprandially, the mix of fuels used for
cellularenergyproductionisdramatically
altered when insulin sensitivity is de-
creased (7–9). The ability to noninva-
sively detect the shift in fuel source
utilization between individuals with nor-
mal glucose tolerance (NGT) and those at
risk for pre-diabetes and early-stage dia-
betes (PDED) has considerable clinical
utility.
It has been demonstrated previously
that
13CO2 in breath is as effective as the
hyperinsulinemic-euglycemic clamp
method for assessing insulin resistance
(10). However, the clinical utility of de-
tecting breath CO2 kinetics using a stan-
dard diagnostic infrared
13CO2 breath
analyzer between individuals with NGT
andthosewithPDEDhasnotbeenclearly
established. Therefore, the aim of the
present study was to evaluate the efﬁcacy
ofadiagnosticbreathanalyzeravailablein
manyphysicianofﬁcestocharacterizethe
kinetics of glucose-derived CO2 in breath
after administration of a standard OGTT
in individuals with NGT and PDED. We
compared the breath CO2 kinetics from
individuals with NGT with those from in-
dividuals with PDED for 10 h after an
OGTT (75-g glucose load) isotopically la-
beled with [U-
13C6]glucose. In addition,
breath CO2 data were correlated with in-
dexes of insulin resistance (whole-body
index of insulin sensitivity [WBISI], ho-
meostasis model assessment of insulin re-
sistance [HOMA-IR], and quantitative
insulinsensitivitycheckindex[QUICKI])
calculated from measures of blood glu-
cose and plasma insulin. We hypothe-
sized that the standard breath analyzer
would be sufﬁciently sensitive to detect
impaired glucose utilization for cellular
respiration during a standard OGTT be-
tween those with NGT and PDED.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
provedbytheUniversityofTexasMedical
Branch (UTMB) Institutional Review
Board and conducted in the UTMB Gen-
eral Clinical Research Center (GCRC). All
subjects provided written informed con-
sent before participating in the study.
Screening of all subjects included fasting
blood glucose, blood cell count, thyroid
functiontest,lipidpanel,urinalysis,anda
urine pregnancy test for premenopausal
women.Individualswithapreviousdiag-
nosis of type 2 diabetes or taking any
medications known to affect glucose or
lipid metabolism were excluded from
participation. On the basis of their 2-h
OGTT blood glucose levels on the study
day, subjects were grouped as either hav-
ing NGT (2-h OGTT blood glucose 7.8
mmol/l, n  10) as outlined by the Amer-
ican Diabetes Association (http://www.
diabetes.org)orhavingPDED(2-hOGTT
blood glucose 7.8–16 mmol/l, n  7). All
subjects with NGT required fasting blood
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ject characteristics are shown in Table 1.
The study protocol consisted of 4
days of study activities (Fig. 1). On days
1–3, subjects consumed a standardized,
low-carbohydrate diet containing 15%
carbohydrate, 25% protein, and 60% fat.
Individualdietaryrequirementsweredeter-
mined by a registered dietitian and calcu-
lated using the Harris Benedict equation
(11). During this diet stabilization period,
all subjects were provided with breakfast,
lunch, and dinner from the UTMB GCRC
metabolic kitchen. All meals were picked
uponadailybasisforconsumptionoff-site.
Subjects were required to completely con-
sume these meals and nothing else except
water. Height and weight were recorded
dailyduringthevisitstotheGCRCforpick-
up of the meals. On the morning of the
fourth day, a 10-h OGTT was performed in
the GCRC.
After an overnight fast (water al-
lowed), subjects were placed in a bed at
the GCRC, and an antecubital venous in-
travenous line was inserted for the collec-
tion of blood samples. Baseline blood
samples were collected twice over a 15-
minute period. During the second base-
line blood collection, simultaneous
breath samples were collected by having
thesubjectsbreatheintobreathcollection
bags ﬁtted with one-way valves. After
the baseline sample collection, a drink
containing 75 g glucose and 150 mg
[U-
13C6]glucose was administered and
consumed within 1 min. From this point
(t  0 min), blood and single-point
breath samples were collected every 30
min for 10 h. For the collection of breath
samples, the subjects were instructed to
breathe normally, hold their breath for
3s,andexhalecompletelyintothecollec-
tion bag provided. Subjects remained at
rest throughout the 10-h OGTT and were
only allowed to move around the room to
use the restroom. Water was provided ad
libitumthroughoutthe10-hOGTT.After
collection of the ﬁnal samples at t  10 h
and removal of the intravenous line, the
subjects were given food and discharged.
Blood glucose
Glucose concentrations were determined
in whole blood immediately after collec-
tion of the samples using a 2300 STAT
Plus Glucose analyzer (intra-assay coefﬁ-
cient of variance [CV]  2.1%).
Plasma insulin
Insulin concentrations were determined
inplasmausinganImmulite2000chemi-
luminescence immunoassay system (Diag-
nostic Products Corporation, Los Angeles,





breath samples were measured using a
UBiT-IR300 infrared spectrophotometer
(Otsuka Electronics, Hirakata, Osaka, Ja-
pan) (CV 1.0%). All results are calcu-
lated as per mille (‰) change of
13CO2
abundance from the baseline breath sam-
ple and expressed as per mille delta over
baseline (‰DOB).
Indexes of insulin resistance
WBISI(12),HOMA-IR(13),andQUICKI
(14) were calculated from blood glucose
(milligrams per deciliter) and plasma in-
sulin (micro-international units per milli-
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A repeated-measures analysis using re-
stricted maximum likelihood estimation
was used to obtain parameter estimates
with the MIXED procedure in SAS (SAS/
STAT 9.1 User’s Guide; SAS Institute,
Cary, NC). Each set of measurements
from the same subject was considered a
Figure 1— Study time line. Subjects followed a 3-day standardized low-carbohydrate diet com-
posed of 15% carbohydrate, 25% protein, and 60% fat. Individual dietary requirements were
determined by a registered dietitian and calculated using the Harris Benedict equation. On the
fourth day, after an overnight fast, a 10-h stable isotopically labeled OGTT was performed, and
blood and breath samples were collected every 30 min.
Table 1—Subject characteristics
NGT PDED P value
2-h OGTT blood glucose (mmol/l) 6.2  0.17 11.4  0.94* 0.0001
Sex (female/male) 5/5 4/3 0.79
Age (years) 47  35 6  5 0.15
Weight (kg) 89  69 2  6 0.74
Height (cm) 166  2 172  3 0.09
BMI (kg/m
2) 31  23 1  2 0.96
Fasting blood glucose (mmol/l) 5.1  0.11 6.8  0.56* 0.003
Fasting plasma insulin (IU/ml) 7.0  1.7 10.39  2.77 0.29
WBISI 8.00  1.22 5.48  1.47 0.10
HOMA-IR 1.63  0.43 3.23  0.94* 0.05
QUICKI 0.37  0.01 0.34  0.01* 0.04
Data are means  SE. *Signiﬁcantly different from NGT (P  0.05).
Dillon and Associates
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AR(1) covariance structures were used.
These models allow for inclusion of sub-
jects with small amounts of missing data.
The mixed model tested the effects for
group, time, and the (group  time) in-
teraction. When the interaction was sig-
niﬁcant (P  0.05) we computed two-
sample t tests at each time point for
descriptive purposes used only in the
ﬁgures.
RESULTS— There were no differ-
ences in age, height, weight, BMI, sex, or
fasting plasma insulin between the NGT
and PDED groups (Table 1). HOMA-IR
was signiﬁcantly higher in the PDED
group, and QUICKI was signiﬁcantly
lower in the PDED group compared with
the NGT group (P  0.05). WBISI was
not signiﬁcantly different between the
groups.
Blood glucose. By design, 2-h OGTT
bloodglucoseconcentrationswerehigher
in the PDED group (11.4  0.95 mmol/l)
compared with the NGT group (6.2 
0.19mmol/l;P0.00001).Therepeated
mixed-model analysis indicated that
blood glucose had signiﬁcant group (P 
0.0001),time(P0.0001),andgroup
time interaction (P  0.0001). The inter-
action indicated that blood glucose con-
centrations were signiﬁcantly higher in
the PDED group compared with the NGT
groupbetween0and3h,asshowninFig.
2A. Fasting blood glucose concentrations
were higher in the PDED group (6.8 
0.56 mmol/l) than in the NGT group
(5.1  0.13 mmol/l; P  0.01). Blood
glucose levels were signiﬁcantly elevated
after the glucose load in the PDED group
compared with the NGT group from t 
0–3.5 h (P  0.05). There were no differ-




The repeated mixed-model analysis indi-
cated that insulin gave effects for group
(P  0.53), time (P  0.0001), and
group  time interaction (P  0.03). The
interaction indicated that the differences
between the PDED and NGT groups were
stronger at later time points than at early
ones, as shown in Fig. 2B.
Breath CO2
Breath
13CO2 abundance had signiﬁcant
group(P0.02),time(P0.0001),and
group  time interaction (P  0.0002).
The interaction indicated that breath
13CO2 abundance was signiﬁcantly lower
in the PDED group compared with the
NGT group between 1 and 3 h after the
glucose load as shown in Fig. 3A. Peak
breath
13CO2 abundance occurred at
3.5 h in the NGT group (41.36  1.56
‰DOB) and at 4.5 h in the PDED group
(36.87  3.15 ‰DOB). Intersubject CVs
at peak
13CO2 appearance were 12 and
22% for the NGT and PDED groups, re-
spectively. Areas under the curve (AUCs)
for breath
13CO2 abundance were calcu-
latedfrom0to4handfrom0to10h(Fig.
3B)a sm e a n SEM. Mean breath
13CO2
abundance AUC was lower in the PDED
group than in the NGT group from 0 to
4 h after the glucose load (P  0.05). The
difference between the PDED and NGT
groups disappeared when AUC was cal-
culated from 0 to 10 h.
Figure 2— Blood glucose and plasma insulin concentrations in individuals with NGT and PDED
during the 10-h OGTT. A: Blood glucose was different between individuals with NGT and PDED
over time as determined by mixed-model repeated measures (P  0.05). *Different between
individuals with NGT and PDED (t test, P  0.05). B: Plasma insulin was different between
individualswithNGTandPDEDovertimeasdeterminedbymixed-modelrepeatedmeasures(P
0.05). *Different between individuals with NGT and PDED (t test, P  0.05).
Breath test of glucose tolerance




surements correlated directly with WBISI
(Pearson correlation coefﬁcient r 
0.502,P0.04)andQUICKI(r0.629,
P  0.007) and inversely with fasting
glucose (r  0.631, P  0.007), 2-h glu-
cose(r0.689,P0.002),HOMA-IR
(r  0.555, P  0.02), and weight
(r  0.546, P  0.02). Signiﬁcant cor-
relations were found between all three
measured indexes of insulin resistance
(P  0.002). No correlations were found
between age and any of the measured
parameters.
CONCLUSIONS— Results of the
presentstudydemonstratethatastandard
infrared breath analyzer can detect differ-
ences in the excretion pattern of glucose-
derived breath CO2 between individuals
with NGT and PDED. Moreover, these
differences were detectable in the time
frame of a standard OGTT and correlated
with the differences in glucose kinetics
between the two groups. Thus, this non-
invasive breath method may assist in rec-
ognition of PDED by providing an
alternative approach for large-scale pop-
ulationtestingwithouttheneedforblood
sampling. This type of testing is particu-
larly important to improve acceptance of
pre-diabetes screening for certain patient
populations, such as pediatric patients,
who may be reluctant to undergo screen-
ing because of the prospect of repeated
blood sampling.
Remarkably, the breath analyzer was
capable of detecting marked differences
in glucose-derived breath CO2 kinetics
betweenindividualswithNGTandPDED
within60minofa10-hOGTT.Theinitial
rate of glucose-derived CO2 appearance
in breath was signiﬁcantly lower in indi-
viduals with PDED compared with those
withNGT.Consistentwiththebloodglu-
cose measurements, the breath test was
able to detect impairments in clearance of
exogenous(oral)glucosefromcirculation
in individuals with PDED. Whereas the
traditional blood glucose measurements
rely on the accumulation of substrate in
circulation,thebreathtestisamoredirect
measure of intracellular glucose metabo-
lism. Impaired glucose uptake due to di-
minished pancreatic insulin secretion or
impaired insulin action on the target tis-
sue (i.e., skeletal muscle) results in
blunted glucose oxidation in individuals
with PDED.
A strength in our present study is that
breath CO2 kinetics were followed over
a longer period (10 h) and included mul-
tiple breath CO2 measurements in con-
junction with simultaneous measure-
ments of both blood glucose and plasma
insulin concentrations. The data expressed
as AUC support the assumption that, al-
though slower in individuals with PDED,
the eventual fate of the oral glucose was
the same as that in individuals with NGT.
Although the mean AUC was higher in
individuals with NGT than in those with
PDED from 1.5 through 4.5 h after glu-
cose ingestion, this difference disap-
peared within the 10-h period. Thus, our
results support the concept that individ-
uals with PDED switch at a slower rate
between lipid and glucose as a source of
metabolicfuelcomparedwithindividuals
with NGT. Impaired glucose tolerance
has been described as “metabolic inﬂexi-
bility” of the target tissue to respond to a
switchfromlipidoxidationtoglucoseox-
idation (7). Under normal physiologic
conditions, cellular fuel consists primar-
ily of free fatty acids (FFAs) and glucose,
Figure 3— Breath
13CO2 abundance and areas under the curve for individuals with NGT and
PDEDduringthe10-hOGTT.A:Breath
13CO2abundancewasdifferentbetweenindividualswith
NGT and PDED over time as determined by mixed-model repeated measures (P  0.05). *Sig-
niﬁcant difference between individuals with NGT and PDED (t test, P  0.05). B: AUCs were
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tion (7,9,15). In the basal state, 60% of
cellular fuel for insulin-dependent pe-
ripheral tissues (muscle) is derived from
FFAs (15–19). In individuals with NGT,
when an oral dose of glucose (75–100 g)
is administered, the contribution of FFAs
to whole-body fuel oxidation is reduced
dramatically, with glucose becoming a
prominent cellular fuel (15). In individu-
alswithinsulinresistanceorpre-diabetes,
this response is signiﬁcantly blunted, re-
sultinginadisproportionatecontribution
of FFAs to postprandial whole-body en-
ergy consumption (20,21). Glucose up-
take through GLUT4 is mediated by
insulin, whereas non–insulin-dependent
glucose uptake occurs through other glu-
cose transporters or mechanisms. In dis-
orders such as type 2 diabetes, the non–
insulin-dependentglucoseuptakemaybe
upregulated to compensate for the lack of
insulin-dependent GLUT4 recruitment,
contributingtoahigher-than-normalglu-
cose oxidation in the fasting state but
lowerinsulin-mediatedglucoseoxidation
in response to a meal (7,20,22).
Although resting energy expenditure
measurements are not available from
these experiments, future studies that in-
clude indirect calorimetry measures are
needed to conﬁrm how resting energy ex-
penditure differences between subjects,
as well as metabolic changes in response
to glucose ingestion, affect CO2 kinetics
in breath. However, it is important to un-
derscore that this breath test technique
is intended as a noninvasive alternative
to blood draws for the determination of
glucose tolerance during a standard
OGTT—not as an alternative to indirect
calorimetry for measurements of whole-
body energy expenditure. This technique
is simple to apply and relatively econom-
ical because it requires few single-breath
collections and no special training, which
may allow for the development of at-
home kits.
Our results are, in general, consistent
with the correlations between glucose-
derived CO2 in breath and indexes of in-
sulinresistancereportedbyLewanczuket
al. (10). This group recently compared a
single measurement of [
13C]glucose-
derived CO2 in breath taken 90 min after
ingestion of a lower dose of glucose to
resultsobtainedfromahyperinsulinemic-
euglycemic clamp performed on a sepa-
rate occasion. Interestingly, although the
methods used in that study were pro-
foundlydifferentfromthoseusedinours,
their correlation coefﬁcient was remark-
ably similar to our 2-h correlation coefﬁ-
cient between breath CO2 and HOMA-IR
(0.531 [10]; 0.555 [ours]) (10).
However,tothebestofourknowledgeno
studies have explored whether glucose-
derived CO2 in breath correlated with
blood glucose and plasma insulin mea-
surements collected simultaneously dur-
ing a labeled OGTT. Our study is also the
ﬁrstdemonstratingfeasibilityoftheuseof
a cost-effective diagnostic breath analyzer
insteadofanisotoperatiomassspectrom-
eter as used previously.
Although low-carbohydrate diets are
not typically prescribed before adminis-
tration of a standard OGTT, the 3-day
low-carbohydrate diet stabilization pe-
riod was intended to remove dietary in-
take as a variable in the present study. In
addition, we intended to decrease hepatic
and muscle glycogen stores, thus mini-
mizingthesetissuesasimmediatesources
ofendogenousglucose.Futureresearchis
warranted to characterize the impact of
diet and altered gastrointestinal absorp-
tion of glucose on the kinetics of breath
CO2 appearance.
Insummary,theresultsofthepresent
study demonstrate the clinical applicabil-
ity of a standard breath analyzer to detect
differences in glucose-derived breath
CO2 kinetics between individuals with
NGTandPDED,whichcorrelatewithdif-
ferences in blood glucose kinetics. After a
baseline sample, the optimal time for
breath collection was between 1 and 3 h
after the oral glucose load, similar to the
time frame of a standard OGTT. Both the
areaunderthecurve,whenmultiplemea-
surements are made over time, and the
slope, when only before and after mea-
surementsareavailable,wereshowntobe
effective. This noninvasive method may
assist in recognition of undiagnosed
PDED in at-risk individuals during the
pre-diabetes stage of type 2 diabetes in a






alyzer and storable breath collection bags
is suitable for large-scale population test-
ing in research as well as the clinical
setting. However, further research is nec-
essary to validate this method as a viable
diagnostictooltobeusedinadditiontoor
in place of existing methods. For exam-
ple,itwillbeimportanttoestablishcutoff
values between individuals with true
NGT and those with PDED, determine
within-subject variability and repeatabil-
ity, elucidate the effects of dietary intake
on breath test results, and explore the ap-
plicability of this method in pediatric
care.
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